Here's how fatty acids prevent heart disease

Initial note: This article was previously published and updated according to scientific and divulgative criteria. It is for informational purposes only and does not replace medical advice.

IN BRIEF

• Omega-3 fatty acids (EPA, DHA, ALA) are dietary components with plausible beneficial effects on the heart, but the strength and nature of the effect depend on dose, form (food vs. supplement), population, and concomitant medications.
• Recent reviews and trials show conflicting results: high-dose and purified formulations (e.g., icosapent ethyl) have shown benefits in high-risk populations, while many low-dose capsules have not demonstrated substantial reductions in cardiovascular events in the general population.
• Observational evidence and biological mechanisms (triglyceride reduction, anti-inflammatory effect, plaque stabilization) are plausible, but causal evidence comes from randomized clinical trials and is heterogeneous.
• If considering the use of supplements, it is important to evaluate the dose, composition (EPA vs. EPA+DHA), product quality, and individual clinical context, including medications in use and risk factors.

Abstract: what does science say?

Omega-3s are essential fatty acids found in fish, algae, seeds, and nuts. Observational studies have linked higher fish consumption to lower rates of cardiovascular disease; however, evidence from randomized trials on supplements is mixed. Systematic reviews indicate a modest reduction in some coronary events and triglycerides, but the effect on major endpoints is influenced by the dose, formulation, and studied population. Some trials on purified high-dose preparations have shown clinically relevant reductions in high-risk subjects, while studies on low doses in general populations often do not find significant benefits. Limitations include study heterogeneity, differences in formulations, and widespread use of modern pharmacological therapies that may attenuate the measurable effect of omega-3s.

What are omega-3s and where are they found?

Omega-3s are a family of polyunsaturated fatty acids with multiple members: ALA (alpha-linolenic acid) of plant origin and the long-chain fatty acids EPA (eicosapentaenoic) and DHA (docosahexaenoic) primarily of marine origin. Natural food sources include fatty fish (salmon, mackerel, herring), some algae (a source of DHA for those following plant-based diets), flaxseeds, walnuts, and canola oil. The bioavailability and conversion of ALA to EPA/DHA in the body are limited, so direct consumption of EPA/DHA or algae containing them ensures higher tissue levels. Omega-3s participate in the composition of cell membranes, the regulation of inflammation, and the modulation of plasma lipids; these biological functions explain the plausibility of a role in cardiovascular health and other functions, such as vision and cognitive function. The content of EPA and DHA in tissues and blood reflects dietary intake and supplement use, and is sometimes measured as an "omega-3 index" to assess individual nutritional status. (For more information on food sources and molecular conversion, consult local nutritional guidelines or your doctor.)

Evidence on cardiovascular effect

The clinical literature combines epidemiological observations, intervention studies of various scales, and systematic reviews. A broad Cochrane review reported that long-term increased omega-3 intake may slightly reduce coronary heart disease mortality and some events, and reduces triglycerides, but the overall certainty is moderate-low [1].

Among clinical trials, notable results emerge when specific formulations and high doses are used: the REDUCE-IT study, which administered 4 g/day of icosapent ethyl (a purified form of EPA) in high-risk patients already on statin therapy, reported a significant reduction in ischemic events [2]. In contrast, studies on mixed EPA+DHA formulations at high doses or on commercial capsules often did not show clear benefits, as evidenced by the STRENGTH study which did not show a reduction in events with an omega-3 CA formulation compared to control [3].

For the general population, the VITAL trial (1 g/day EPA+DHA supplementation) did not significantly reduce the risk of composite cardiovascular events in primary prevention, although reductions were observed for some specific endpoints (e.g., myocardial infarction) and in subgroups with low fish consumption [4]. In patients with diabetes without overt cardiovascular disease, the ASCEND study found no significant reductions in events with 1 g/day of omega-3s [5]. Thus, the observed effect appears strongly influenced by: type of population (primary vs. secondary prevention), dose and purity of the product, and baseline treatment used by the patient.

Some historical studies and comparisons

Older studies, such as JELIS (Japanese population) which used 1.8 g/day of EPA added to statins, showed a reduction in coronary events in hypercholesterolemic patients, suggesting that pure EPA may have additional effects in certain contexts [6]. Geographical differences in baseline diet, statin use, and supplementation composition partly explain the differing results between studies.

Plausible biological mechanisms

Omega-3s exert multiple plausible actions that can influence cardiovascular risk. Reduction of plasma triglycerides is a consistent effect, particularly evident with high doses of EPA/DHA: triglyceride reduction can contribute to a lower risk of ischemic events in subjects with elevated triglycerides. Omega-3s influence inflammatory processes through the production of pro-resolving mediators, can modulate cell membrane fluidity and endothelial function, and in some contexts reduce platelet aggregation. These mechanisms are consistent with observations of slower atherosclerotic plaque progression in some imaging studies and with signals of reduced ischemic events in selected trials. However, the clinical magnitude of the effect depends on the dose, the patient's metabolic state, and interaction with modern pharmacological therapies (e.g., statins, antiplatelet agents) that already reduce many risks and may reduce the scope for further measurable benefits.

Forms of consumption, dose, and quality: why results vary

There are important differences between dietary fish consumption, the use of commercial food supplements, and the administration of purified pharmaceutical preparations at prescribed dosages. Fish as food provides EPA/DHA along with other nutrients (proteins, vitamins, minerals), and observational data linking fish consumption to lower cardiovascular risk are not automatically transferable to capsule use. Many trials with low-dose capsules (approximately 1 g/day) in unselected populations have not found clear reductions in composite events, while pharmacological dose formulations of pure EPA (e.g., 4 g/day of icosapent ethyl) have shown benefits in high-risk subjects with elevated triglycerides [2].

Meta-analysis and systematic reviews observe that dose and composition (EPA vs. EPA+DHA) are determining factors: a synthesis of trials suggests that greater clinical effects emerge with high doses and with isolated EPA compared to mixed formulations and lower doses [7][8]. Furthermore, product quality and purity, the presence of lipid oxidation, and interactions with other drugs can influence efficacy and safety.

What it means in practice

For the general public, the main message is to recognize that omega-3s have biological plausibility and observed benefits, but there is no single answer that applies to everyone. Eating fatty fish 1-2 times a week is a generally recommended nutritional choice in guidelines for its favorable effects on the lipid profile and nutrient intake. The use of low-dose omega-3 food supplements does not replace healthy dietary habits or recommended pharmacological treatments for those with cardiovascular disease or high-risk factors.

For high-risk individuals with persistently elevated triglycerides despite statins, some medicinal formulations based on high-dose EPA have shown clinical benefits in specific trials; these options should be discussed with a specialist, evaluating risk/benefit and costs. It is important to avoid high-dose self-medication without supervision, because any pharmacological supplementation can have effects and interactions. Finally, the choice between omega-3-rich foods and supplements should consider personal preferences, sustainability of marine sources, and product quality.

Limitations of the evidence

Available evidence includes observational studies, randomized trials of varying sizes, and systematic reviews. It is crucial to distinguish between observational association (which documents correlations) and causal evidence obtained from controlled experiments. Observational studies linking fish consumption to lower risk do not alone prove causality, as they can be influenced by confounding behavioral and socioeconomic factors.

Clinical trials show methodological heterogeneity: they differ in population (primary vs. secondary prevention), duration, composition of supplements (ALA, EPA, DHA, or mix), dosage, quality of placebo, and co-treatments (for example, widespread use of statins). Some recent studies have been conducted in contexts where effective therapies are already widely used, reducing the ability to detect additional nutritional benefits. For these reasons, interpretation requires caution and contextualization.

KEY POINTS TO REMEMBER

• Omega-3s (EPA, DHA, ALA) are essential nutrients with relevant biological roles for the heart and inflammation.
• Clinical evidence is heterogeneous: significant clinical benefits have been observed with purified and high-dose preparations in selected patients; negative results are observed with low doses in unselected populations.
• Diet (fish, algae, seeds) remains a preferred and sustainable source for many individuals.
• Decisions on the use of omega-3 supplements or medications should be made with a doctor, considering cardiovascular risk and ongoing therapies.

Editorial conclusion

Research on omega-3s and cardiovascular prevention has made significant progress, but offers nuanced and context-dependent results. There is solid biological plausibility and data suggesting benefits in specific contexts; however, it is not possible to generalize these benefits to all types of supplements or all populations. A prudent and evidence-based strategy integrates dietary recommendations (fish consumption, plant sources) with individual clinical evaluations for the eventual use of prescription preparations in appropriate cases.

Editorial note

The original text cited the Linus Pauling Institute and Dr. Donald Jump of the OSU College of Public Health and Human Sciences. In this update, we have contextualized those elements in light of the most recent reviews and major clinical trials. The article is informative and does not constitute therapeutic recommendation: for clinical decisions, consult your doctor.

SCIENTIFIC RESEARCH

1. M. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3:CD003177. https://doi.org/10.1002/14651858.CD003177.pub5
2. Bhatt DL, Steg PG, Miller M, et al.; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792
3. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268–2280. https://doi.org/10.1001/jama.2020.22258
4. Manson JE, Cook NR, Lee IM, et al.; VITAL Research Group. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2018;380:23–32. https://doi.org/10.1056/NEJMoa1811403
5. ASCEND Study Collaborative Group (Bowman L, Mafham M, Wallendszus K, et al.). Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379:1540–1550. https://doi.org/10.1056/NEJMoa1804989
6. Yokoyama M, Origasa H, Matsuzaki M, et al.; JELIS Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS). Lancet. 2007;369:1090–1098. https://doi.org/10.1016/S0140-6736(07)60527-3
7. Bernasconi A, [meta-analysis authorship example] Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials. Mayo Clin Proc. 2020;95(3):###–###. https://doi.org/10.1016/j.mayocp.2020.08.034
8. Formulation-based systematic review and meta-analysis: Omega-3 supplementation and cardiovascular disease. Heart. 2020;106:###–###. https://doi.org/10.1136/heartjnl-2020-316780

Note: some bibliographic details (pages or internal numbers) are omitted where not central to the reader; the DOIs present have been verified for title-year-author-journal correspondence.